Introduction {#sec1}
============

It is known that quinolin-2(1*H*)-ones and their heterocycle-fused hybrid scaffolds exhibit biological and pharmacological properties.^[@ref1]^ Besides classical synthetic methods for quinolin-2(1*H*)-ones,^[@ref2]^ many transition-metal-catalyzed and -free synthetic versions have recently been attempted as alternative methods from the viewpoint of the wide availability of substrates. Several representative examples are shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. Larock and Jiao reported that N-substituted *o*-iodoanilines and simple anilines undergo carbonylative cyclization with internal alkynes in the presence of a palladium or rhodium catalyst to give quinolin-2(1*H*)-ones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route a).^[@ref2]−[@ref4]^ Inamoto and Doi reported palladium-catalyzed intramolecular amidation of *N*-tosyl-3,3-diarylacrylamides via C(sp^2^)--H bond activation for the synthesis of such a scaffold ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route b).^[@ref5]^ Such a similar reaction through C--H activation was shown by palladium-catalyzed coupling and cyclization of simple anilines with ethyl acrylates ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route c).^[@ref6]^ Fujiwara and Vadola also demonstrated palladium- and gold-catalyzed intramolecular hydroarylation of *N*-aryl alkynamides leading to quinolin-2(1*H*)-ones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route d).^[@ref7]^ Acetanilides were found to be coupled and cyclized with propiolates and acrylates in the presence of a ruthenium catalyst along with a carboxylic acid to form quinolin-2(1*H*)-ones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route e).^[@ref8]^ Such a similar coupling and cyclization was also exemplified by the iridium-catalyzed annulation of *N*-arylcarbamoyl chlorides with internal alkynes ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route f).^[@ref9]^ Wang et al. have shown that α-carbamoyl ketene dithioacetals react with *o*-(trimethylsilyl)phenyl triflate in the presence of a palladium catalyst to give quinolin-2(1*H*)-ones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route g).^[@ref10]^ In addition to these transition-metal-catalyzed synthetic methods shown in routes a--g of [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, it is reported that quinolin-2(1*H*)-ones also can be eco-friendly when synthesized by transition-metal-free lactamization of 2-alkenylanilines under carbon dioxide atmosphere in the presence of NaO^*t*^Bu ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, route h).^[@ref11]^ Besides the abovementioned representative examples, many other transition-metal-catalyzed and -free protocols for quinolin-2(1*H*)-ones have also been developed and documented.^[@ref12]^ In connection with this report, as part of our ongoing studies on cyclization reactions,^[@ref13]^ we recently reported that aryl 2-bromobenzoates and their analogues are readily cyclized by microwave irradiation to afford 6*H*-benzo\[*c*\]chromen-6-ones and their analogues, respectively.^[@ref14]^ The present work arose during the course of application of such a cyclization protocol to the reaction with amide analogues, *N*-aryl-β-bromo-α,β-unsaturated amides. Herein, this report provides transition-metal-free microwave-assisted lactamization of such starting amides leading to quinolin-2(1*H*)-ones and phenanthridin-6(5*H*)-ones under mildly basic conditions.

![Representative Synthetic Routes for Quinolin-2(1*H*)-ones](ao-2018-01742x_0001){#sch1}

Results and Discussion {#sec2}
======================

On the basis of our recent report on microwave-assisted lactonization of aryl 2-bromobenzoates and their analogues leading to 6*H*-benzo\[*c*\]chromen-6-ones and their 7,8,9,10-tetrahydro analogues under mildly basic conditions, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} shows several attempted results for the lactamization of 2-bromo-*N*-phenylcyclohex-1-enecarboxamide (**1a**), leading to 7,8,9,10-tetrahydrophenanthridin-6(5*H*)-one (**2a**).^[@ref14]^ It is known that *N*-aryl-2-halobenzamides are readily cyclized into phenanthridinones under KO^*t*^Bu and a catalytic amount of 1,10-phenanthroline.^[@ref15]^ However, treatment of **1a** in dimethylformamide (DMF) at 100 °C for 0.5 h in the presence of K~2~CO~3~ (5 equiv) along with 1,10-phenanthroline under microwave irradiation (100 W of initial power) did not afford **2a** at all, and **1a** was recovered almost completely ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). No cyclized product **2a** was also observed with changing 1,10-phenanthroline to [l]{.smallcaps}-proline ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2). The reaction temperature was critical for the formation of **2a**, and the yield of **2a** increased with the increase in temperature up to 150 °C ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--4). Prolonging the reaction time up to 2 h was needed for the effective formation of **2a** with complete conversion of **1a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 4--6). As is the case for the lactonization of aryl 2-bromobenzoates and their analogues, the reaction also proceeded in the absence of a ligand ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 7--9). During the same period of reaction time, the yield of **2a** increased from 57% (60% conv of **1a**) and 72% (81% conv of **1a**) to 89% (100% conv of **1a**). A lower yield of **2a** and conversion of **1a** were observed with a lower amount of K~2~CO~3~ ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 10 and 11). The reaction also proceeded using other bases such as KOH, Cs~2~CO~3~, K~3~PO~4~, and KO^*t*^Bu, but the yield of **2a** was generally lower than that with the use of K~2~CO~3~ except for KO^*t*^Bu, which exhibited a similar activity as K~2~CO~3~ ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 12--15). A weak base is of great advantage to a strong base in terms of tolerance for functional groups in an organic transformation. Treatment of **1a** under usual heating for 24 h at 150 °C afforded **2a** in only 23% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 16). As a result, K~2~CO~3~ was shown to be the base of choice and inductively coupled plasma-atomic emission spectroscopy analysis of commercial K~2~CO~3~ showed ND (Not Detected, below method detection limit, 5--10 ppm) of transition metals such as Co, Cu, Ni, Fe, and Pd.

###### Optimization of Conditions for the Reaction of **1a**[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-01742x_0005){#GRAPHIC-d7e520-autogenerated}

  entry                                base (mmol)        additive                  temp (°C)   time (h)   yield[b](#t1fn2){ref-type="table-fn"} (%)
  ------------------------------------ ------------------ ------------------------- ----------- ---------- -------------------------------------------
  1                                    K~2~CO~3~ (1.5)    1,10-phenanthroline       100         0.5        0
  2                                    K~2~CO~3~ (1.5)    [l]{.smallcaps}-proline   100         0.5        trace
  3                                    K~2~CO~3~ (1.5)    [l]{.smallcaps}-proline   120         0.5        37
  4                                    K~2~CO~3~ (1.5)    [l]{.smallcaps}-proline   150         0.5        59
  5                                    K~2~CO~3~ (1.5)    [l]{.smallcaps}-proline   150         1          69
  6                                    K~2~CO~3~ (1.5)    [l]{.smallcaps}-proline   150         2          88
  7                                    K~2~CO~3~ (1.5)                              150         0.5        57
  8                                    K~2~CO~3~ (1.5)                              150         1          72
  9                                    K~2~CO~3~ (1.5)                              150         2          89
  10                                   K~2~CO~3~ (0.3)                              150         2          19
  11                                   K~2~CO~3~ (0.9)                              150         2          63
  12                                   KOH (1.5)                                    150         2          34
  13                                   Cs~2~CO~3~ (1.5)                             150         2          34
  14                                   K~3~PO~4~ (1.5)                              150         2          72
  15                                   KO^*t*^Bu (1.5)                              150         2          90
  16[c](#t1fn3){ref-type="table-fn"}   K~2~CO~3~ (1.5)                              150         24         23

Reaction conditions: **1a** (0.3 mmol), additive (0.09 mmol), and DMF (3 mL), under microwave irradiation (100 W of initial power) and N~2~, unless otherwise stated.

Isolated yield.

Under usual heating (screw-capped vial).

[Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} shows the results for the cyclization of various *N*-aryl-β-bromo-α,β-unsaturated amides such as *N*-aryl-2-bromo-1-cycloalkenecarboxamides and *N*-aryl-3-bromoacrylamides under the optimized conditions. The amides (**1b** and **1c**) having a methyl group at para- and ortho-positions to N on the N-attached phenyl ring were also cyclized to give the corresponding 7,8,9,10-tetrahydrophenanthridin-6(5*H*)-ones (**2b** and **2c**) selectively in similar yields. The cyclization of 2-bromo-*N*-phenylcyclohex-1-enecarboxamides (**1d** and **1e**) having methyl and phenyl substituents on a cyclohexene ring proceeded likewise to give 7,8,9,10-tetrahydrophenanthridin-6(5*H*)-ones (**2d** and **2e**), irrespective of the presence of such substituents on **1d** and **1e**. From the reaction of the amides (**1f--i**) having various ring sizes, the corresponding cyclized products **2f--i** were also formed in the range of 74--86% yields. For testing the effect of the position of bromide and carbamoyl groups on benzo-fused amides, **1j** and **1k** were employed. The cyclization took place irrespective of the position. As is the case for the lactonization of benzo-fused phenyl 2-bromocyclohex-1-enecarboxylates, in the reaction with **1k**, in addition to the expected product **2k**, benzo\[*i*\]phenanthridin-5(6*H*)-one (**2k′**) was produced by dehydrogenation of the initially formed **2k** and/or initial dehydrogenation of the starting **1k** followed by cyclization under the employed conditions.^[@ref14]^ Such a similar dehydrogenation was observed in our recent reports on transition-metal-catalyzed and -free cyclization reactions.^[@cit13a],[@ref16]^ A similar treatment of 3-bromo-*N*-phenylacrylamides **1l--o** under the employed conditions also afforded the corresponding quinolin-2(1*H*)-ones **2l--o**, and the product yield was lower than that when previously described *N*-aryl-2-bromo-1-cycloalkenecarboxamides were used.

###### Scope of the Cyclization Reaction[a](#t2fn1){ref-type="table-fn"}

![](ao-2018-01742x_0006){#GRAPHIC-d7e1094-autogenerated}

![](ao-2018-01742x_0007){#gr5}

Reaction conditions: **1** (0.3 mmol), K~2~CO~3~ (1.5 mmol), DMF (3 mL), 150 °C, and 2 h, under microwave irradiation (100 W of initial power) and N~2~.

The present protocol can be extended to the reaction with *N*-aryl-2-bromobenzamides, which eventually leads to phenanthridin-6(5*H*)-ones. Phenanthridin-6(5*H*)-ones are naturally occurring scaffolds and exhibit a wide spectrum of biological activities.^[@ref17]^ Many transition-metal-catalyzed and -free synthetic methods have been attempted for the construction of such scaffolds, and several representative synthetic routes are shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"} (routes a--h).^[@ref17],[@ref18]^ Treatment of 2-bromo-*N*-phenylbenzamide (**1p**) under the optimized conditions shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} afforded phenanthridin-6(5*H*)-one (**2p**) in 85% yield. With *N*-aryl-2-bromobenzamides (**1q** and **1r**) having the methyl group at para- and ortho-positions to N on the N-attached phenyl ring, the cyclized products (**2q** and **2r**) were selectively formed in similar yields as observed in the reaction with **1b** and **1c**. From the reaction of 2-bromo-*N*-*m*-tolylbenzamide (**1s**), the corresponding cyclized products were obtained as a regioisomeric mixture (**2s** and **2s′**), and the molar ratio was calculated by the integration of clearly separated methyl signals in the ^1^H NMR spectrum.^[@cit18a]^ 2-Bromo-*N*-phenylbenzamides (**1t** and **1u**) having methyl and methoxy substituents on the bromoaryl moiety are also cyclized to give the corresponding phenanthridin-6(5*H*)-ones (**2t** and **2u**). Not shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} is the reaction of 2-bromo-5-fluoro-*N*-phenylbenzamide having F at the para-position to Br, which did not proceed at all toward the cyclization, and the starting material was recovered intact.

![Representative Synthetic Routes for Phenanthridin-6(5*H*)-ones](ao-2018-01742x_0002){#sch2}

As to the reaction pathway, although it is not yet fully understood, this seems to proceed via an initial K~2~CO~3~-induced single-electron transfer to produce **3** and subsequent 6-exo/endo-trig homolytic aromatic substitution (route a) in preference to a 5-exo-trig ipso mode (route b, [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).^[@ref14]^ When the reaction was carried out with the addition of radical scavengers such as 2,2,6,6-(tetramethylpiperidin-1-yl)oxyl, galvinoxyl, or 2,6-di-*tert*-butyl-4-methylphenol (equimolar amount to **1a**) under the employed conditions, **2a** was formed in only 15--29% yields. This experimental observation supports evidence for the radical pathway. A similar radical pathway has been proposed by us and others.^[@ref14],[@ref15],[@ref19]^ We confirmed that treatment of **1a** with 2 equiv of iodobenzene (**4**) under the employed conditions gave **2a** in 68% yield along with the cross-coupled product **5a** (14% yield) and biphenyl (**6**) (5% yield) ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). A similar treatment of *o*-methyl substituted amide **1v** with **4** afforded the cross-coupled product **5b** in 61% yield along with **6** (6% yield). As reported in similar KO^*t*^Bu-mediated radical cyclizations, the formation of **5a** or **5b** indicates that the present reaction proceeds via a radical pathway.

![Reaction Pathway](ao-2018-01742x_0003){#sch3}

![Experiment for the Mechanism Study](ao-2018-01742x_0004){#sch4}

Conclusions {#sec3}
===========

In summary, we have developed a transition-metal-free synthetic method for quinolin-2(1*H*)-ones and phenanthridin-6(5*H*)-ones by K~2~CO~3~-promoted radical cyclization of *N*-aryl-β-bromo-α,β-unsaturated amides and *N*-aryl-2-bromobenzamides under microwave irradiation. The present reaction provides a new synthetic approach for such lactam scaffolds, and a continuous study of synthetic applications for carbo- and heterocycles using such a weak base-promoted transition-metal-free cyclization under microwave irradiation is in progress.

Experimental Procedures {#sec4}
=======================

General {#sec4.1}
-------

^1^H NMR (500 MHz) and ^13^C NMR (125 MHz) spectra were recorded in DMSO-*d*~6~ or CDCl~3~. The melting points were measured with a Stanford Research Inc. MPA100 automated melting point apparatus. The high-resolution mass spectrometry (HRMS) data were recorded using electronic ionization (EI, magnetic sector-electric sector double focusing mass analyzer) at Korea Basic Science Center (Daegu). Microwave reactions (CEM, Discover LabMate) were performed in a 5 mL sealed tube, and the reaction temperature was maintained by an external infrared sensor. The desired products were separated by thin-layer (a glass plate coated with Kieselgel 60 GF~254~, Merck) chromatography (TLC). The amides **1** were synthesized from the corresponding carboxylic acids by subsequent treatment of oxalyl chloride and anilines.^[@ref15],[@cit18n]^ Commercially available reagents were used without further purification.

General Procedure for the Synthesis of **2** {#sec4.2}
--------------------------------------------

To a 5 mL microwave reaction tube was added **1** (0.3 mmol), K~2~CO~3~ (0.208 g, 1.5 mmol), and DMF (3 mL). After stirring at room temperature for 5 min followed by flushing with N~2~ and sealing the tube, the reaction mixture was stirred at 150 °C for 2 h by microwave irradiation at 100 W initial power. The mixture was cooled to room temperature and filtered through a short silica gel column (dichloromethane/MeOH = 8:2) to eliminate inorganic salts. Evaporation of the solvent under reduced pressure gave a crude mixture, which was separated by TLC (dichloromethane/MeOH = 97:3) to afford **2**. Spectroscopic data for all lactams are shown below.

### 7,8,9,10-Tetrahydrophenanthridin-6(5*H*)-one (**2a**)^[@ref20]^ {#sec4.2.1}

*R*~f~ = 0.51. White solid (53 mg, 89%). mp 270--273 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.68--1.73 (m, 2H), 1.76--1.80 (m, 2H), 2.44--2.47 (m, 2H), 2.79--2.82 (m, 2H), 7.14--7.17 (m, 1H), 7.28 (d, *J* = 7.5 Hz, 1H), 7.40--7.43 (m, 1H), 7.65 (d, *J* = 7.7 Hz, 1H), 11.58 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.4, 21.5, 23.5, 24.8, 115.1, 119.5, 121.5, 123.1, 128.0, 128.8, 136.8, 142.6, 161.6.

### 2-Methyl-7,8,9,10-tetrahydrophenanthridin-6(5*H*)-one (**2b**)^[@ref21]^ {#sec4.2.2}

*R*~f~ = 0.56. White solid (59 mg, 92%). mp 287--290 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.66--1.71 (m, 2H), 1.72--1.77 (m, 2H), 2.29 (s, 3H), 2.45--2.48 (m, 2H), 2.64--2.67 (m, 2H), 7.07 (d, *J* = 8.4 Hz, 1H), 7.14 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.42 (s, 1H), 11.58 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 20.7, 21.0, 21.2, 23.7, 24.8, 116.0, 119.5, 122.7, 123.2, 130.8, 133.1, 134.7, 135.8, 161.6.

### 4-Methyl-7,8,9,10-tetrahydrophenanthridin-6(5*H*)-one (**2c**)^[@ref21]^ {#sec4.2.3}

*R*~f~ = 0.57. White solid (56 mg, 87%). mp 293--295 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.74--1.79 (m, 2H), 1.80--1.85 (m, 2H), 2.41 (s, 3H), 2.54--2.57 (m, 2H), 2.73--2.75 (m, 2H), 7.10--7.13 (m, 1H), 7.26 (d, *J* = 7.3 Hz, 1H), 7.37 (d, *J* = 7.9 Hz, 1H), 11.60 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 16.9, 20.8, 20.9, 23.4, 24.6, 119.2, 120.1, 122.7, 122.8, 125.3, 130.9, 132.3, 134.5, 161.2.

### 8-Methyl-7,8,9,10-tetrahydrophenanthridin-6(5*H*)-one (**2d**) {#sec4.2.4}

*R*~f~ = 0.55. White solid (58 mg, 90%). mp 278--281 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.05 (d, *J* = 6.6 Hz, 3H), 1.30--1.38 (m, 1H), 1.70--1.77 (m, 1H), 1.90--1.95 (m, 2H), 2.68--2.79 (m, 2H), 2.95--3.01 (m, 1H), 7.15--7.18 (m, 1H), 7.28 (d, *J* = 7.3 Hz, 1H), 7.41--7.44 (m, 1H), 7.67 (d, *J* = 8.0 Hz, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.5, 24.9, 27.5, 29.6, 31.9, 115.1, 119.4, 121.5, 123.3, 127.6, 128.9, 136.8, 142.3, 161.6. HRMS (EI): Anal. Calcd for C~14~H~15~NO (M^+^), 213.1154; found, 213.1153.

### 8-Phenyl-7,8,9,10-tetrahydrophenanthridin-6(5*H*)-one (**2e**) {#sec4.2.5}

*R*~f~ = 0.48. White solid (67 mg, 81%). mp 305--307 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.87--1.97 (m, 1H), 2.08--2.14 (m, 1H), 2.36--2.46 (m, 1H), 2.88--2.95 (m, 3H), 3.05--3.10 (m, 1H), 7.18--7.21 (m, 1H), 7.22--7.25 (m, 1H), 7.31--7.36 (m, 5H), 7.44--7.47 (m, 1H), 7.71 (d, *J* = 8.0 Hz, 1H), 11.65 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 25.5, 28.5, 30.7, 31.5, 115.1, 119.3, 121.6, 123.4, 126.2, 126.8, 127.6, 128.4, 129.0, 136.9, 142.3, 146.0, 161.4. HRMS (EI): Anal. Calcd for C~19~H~17~NO (M^+^), 275.1310; found, 275.1307.

### 1,2,3,5-Tetrahydro-4*H*-cyclopenta\[*c*\]quinolin-4-one (**2f**)^[@ref22]^ {#sec4.2.6}

*R*~f~ = 0.45. White solid (43 mg, 78%). mp 259--262 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.09--2.16 (m, 2H), 2.82--2.89 (m, 4H), 7.20--7.23 (m, 1H), 7.34 (d, *J* = 7.5 Hz, 1H), 7.46--7.49 (m, 1H), 7.71 (d, *J* = 7.7 Hz, 1H), 11.64 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 23.0, 29.7, 34.6, 115.3, 119.0, 121.6, 124.0, 129.2, 133.3, 137.6, 149.5, 161.4.

### 5,7,8,9,10,11-Hexahydro-6*H*-cyclohepta\[*c*\]quinolin-6-one (**2g**)^[@ref23]^ {#sec4.2.7}

*R*~f~ = 0.46. White solid (55 mg, 86%). mp 269--272 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.44--1.48 (m, 2H), 1.55--1.59 (m, 2H), 1.82--1.86 (m, 2H), 2.86--2.88 (m, 2H), 3.00--3.02 (m, 2H), 7.14--7.17 (m, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.41--7.46 (m, 1H), 7.82 (d, *J* = 8.1 Hz, 1H), 11.63 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 24.9, 25.2, 25.7, 27.2, 31.7, 115.3, 119.0, 121.6, 123.9, 129.2, 133.3, 137.6, 149.4, 161.3.

### 7,8,9,10,11,12-Hexahydrocycloocta\[*c*\]quinolin-6(5*H*)-one (**2h**)^[@ref24]^ {#sec4.2.8}

*R*~f~ = 0.46. White solid (55 mg, 81%). mp 265--268 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.26--1.31 (m, 2H), 1.42--1.46 (m, 2H), 1.55--1.59 (m, 2H), 1.70--1.74 (m, 2H), 2.77--2.79 (m, 2H), 3.04--3.06 (m, 2H), 7.14--7.18 (m, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.40--7.43 (m, 1H), 7.74 (d, *J* = 8.1 Hz, 1H), 11.60 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 24.9, 25.5, 25.8, 26.7, 29.1, 29.7, 115.3, 118.6, 121.6, 124.2, 129.0, 131.5, 137.7, 145.7, 161.1.

### 7,8,9,10,11,12,13,14,15,16-Decahydrocyclododeca\[*c*\]quinolin-6(5*H*)-one (**2i**) {#sec4.2.9}

*R*~f~ = 0.48. White solid (63 mg, 74%). mp 276--278 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.16--1.22 (m, 2H), 1.24--1.41 (m, 10H), 1.52--1.63 (m, 4H), 2.29--2.33 (m, 2H), 2.40--2.43 (m, 2H), 7.05--7.08 (m, 1H), 7.18 (d, *J* = 7.5 Hz, 1H), 7.31--7.34 (m, 1H), 7.56 (d, *J* = 7.7 Hz, 1H), 11.49 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.9, 22.9, 23.9, 24.0, 25.3, 25.6, 25.8, 25.9, 26.3, 29.2, 115.5, 119.0, 122.0, 123.7, 127.7, 129.6, 137.6, 141.9, 163.0. HRMS (EI): Anal. Calcd for C~19~H~25~NO (M^+^), 283.1936; found, 283.1939.

### 7,8-Dihydrobenzo\[*k*\]phenanthridin-6(5*H*)-one (**2j**)^[@ref25]^ {#sec4.2.10}

*R*~f~ = 0.51. White solid (62 mg, 83%). mp 246--248 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.84--2.87 (m, 2H), 3.03--3.06 (m, 2H), 7.23--7.26 (m, 3H), 7.27--7.29 (m, 1H), 7.35 (dd, *J* = 8.2, 1.0 Hz, 1H), 7.50--7.54 (m, 1H), 7.93 (d, *J* = 7.5 Hz, 1H), 8.65--8.67 (m, 1H), 11.88 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 23.5, 27.0, 115.1, 118.6, 121.9, 123.4, 124.6, 125.9, 127.0, 127.3, 127.5, 130.2, 131.6, 136.5, 137.8, 145.8, 160.2.

### 11,12-Dihydrobenzo\[*i*\]phenanthridin-5(6*H*)-one (**2k**) {#sec4.2.11}

*R*~f~ = 0.58. White solid (46 mg, 62%). mp 241--243 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.83--2.86 (m, 2H), 3.02--3.05 (m, 2H), 7.20--7.25 (m, 3H), 7.26--7.29 (m, 1H), 7.35 (dd, *J* = 8.2, 1.0 Hz, 1H), 7.49--7.52 (m, 1H), 7.92 (dd, *J* = 8.2, 0.9 Hz, 1H), 8.66--8.67 (m, 1H), 11.88 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 23.5, 27.0, 115.1, 118.6, 121.9, 123.4, 124.6, 125.9, 127.0, 127.3, 127.5, 130.2, 131.6, 136.6, 137.8, 145.9, 160.2. HRMS (EI): Anal. Calcd for C~17~H~13~NO (M^+^), 247.0997; found, 247.0996.

### Benzo\[*i*\]phenanthridin-5(6*H*)-one (**2k′**) {#sec4.2.12}

*R*~f~ = 0.58. White solid (16 mg, 21%). mp 289--291 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.31--7.33 (m, 1H), 7.47 (dd, *J* = 8.2, 1.1 Hz, 1H), 7.54--7.59 (m, 2H), 7.67--7.70 (m, 1H), 7.73--7.77 (m, 1H), 8.10 (dd, *J* = 8.0, 1.4 Hz, 1H), 8.36 (d, *J* = 8.8 Hz, 1H), 8.56 (d, *J* = 7.8 Hz, 1H), 10.24 (d, *J* = 8.7 Hz, 1H), 11.99 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 115.5, 117.5, 119.1, 120.4, 122.2, 124.1, 126.2, 126.7, 127.2, 128.2, 128.5, 130.1, 132.6, 134.0, 135.7, 136.9, 162.1. HRMS (EI): Anal. Calcd for C~17~H~11~NO (M^+^), 245.0841; found, 245.0839.

### 4-Phenylquinolin-2(1*H*)-one (**2l**)^[@cit12h]^ {#sec4.2.13}

*R*~f~ = 0.41. White solid (44 mg, 67%). mp 234--236 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.91 (s, 1H), 7.15--7.18 (m, 1H), 7.28 (d, *J* = 7.3 Hz, 1H), 7.41--7.44 (m, 1H), 7.60--7.71 (m, 5H), 7.77 (d, *J* = 8.0 Hz, 1H), 12.87 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 116.7, 119.6, 120.7, 122.5, 126.9, 128.5, 128.8, 130.6, 137.2, 139.0, 153.5, 164.3.

### 3-Methyl-4-phenylquinolin-2(1*H*)-one (**2m**) {#sec4.2.14}

*R*~f~ = 0.42. White solid (50 mg, 71%). mp 243--245 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.01 (s, 3H), 7.02 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.12--7.16 (m, 1H), 7.24--7.27 (m, 2H), 7.38 (dd, *J* = 8.3, 1.1 Hz, 1H), 7.45--7.52 (m, 2H), 7.53--7.56 (m, 2H), 11.34 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 22.1, 114.9, 119.1, 121.4, 123.2, 127.9, 128.5, 128.8, 128.9, 129.5, 136.7, 142.1, 145.8, 161.2. HRMS (EI): Anal. Calcd for C~16~H~13~NO (M^+^), 235.0997; found, 235.0095.

### 3-Butyl-4-phenylquinolin-2(1*H*)-one (**2n**) {#sec4.2.15}

*R*~f~ = 0.48. White solid (60 mg, 72%). mp 249--251 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 0.79 (t, *J* = 7.4 Hz, 3H), 1.19--1.30 (m, 2H), 1.42--1.48 (m, 2H), 2.42--2.45 (m, 2H), 7.14--7.17 (m, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.31--7.35 (m, 2H), 7.41--7.45 (m, 1H), 7.48--7.54 (m, 3H), 7.82 (d, *J* = 8.1 Hz, 1H), 11.43 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 13.6, 22.3, 28.9, 33.4, 113.9, 118.8, 120.4, 122.8, 128.0, 128.2, 128.5, 128.8, 129.2, 135.0, 142.1, 145.4, 160.9. HRMS (EI): Anal. Calcd for C~19~H~19~NO (M^+^), 277.1467; found, 277.1469.

### 3,4-Diphenylquinolin-2(1*H*)-one (**2o**) {#sec4.2.16}

*R*~f~ = 0.53. White solid (67 mg, 75%). mp 277--279 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.24--7.26 (m, 4H), 7.29--7.31 (m, 3H), 7.32--7.36 (m, 2H), 7.41--7.44 (m, 3H), 7.56 (dd, *J* = 8.3, 0.8 Hz, 1H), 7.64--7.67 (m, 1H), 11.25 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 117.2, 121.0, 122.0, 124.6, 127.4, 128.1, 128.2, 128.3, 128.7, 128.8, 129.8, 131.0, 131.9, 134.3, 134.9, 152.0, 161.7. HRMS (EI): Anal. Calcd for C~21~H~15~NO (M^+^), 297.1154; found, 297.1156.

### Phenanthridin-6(5*H*)-one (**2p**)^[@ref15]^ {#sec4.2.17}

*R*~f~ = 0.58. White solid (mg, 85%). mp 306--309 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.22--7.29 (m, 1H), 7.32--7.40 (m, 1H), 7.44--7.52 (m, 1H), 7.61--7.68 (m, 1H), 7.80--7.88 (m, 1H), 8.33 (dd, *J* = 8.0, 1.5 Hz, 1H), 8.41 (d, *J* = 8.1 Hz, 1H), 8.44--8.54 (m, 1H), 11.69 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 116.1, 117.6, 122.3, 122.6, 123.3, 125.7, 127.5, 127.9, 129.6, 132.8, 134.3, 136.6, 160.8.

### 2-Methylphenanthridin-6(5*H*)-one (**2q**)^[@cit18m]^ {#sec4.2.18}

*R*~f~ = 0.52. White solid (56 mg, 89%). mp 255--259 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.41 (s, 3H), 7.28--7.32 (m, 2H), 7.58--7.61 (m, 1H), 7.82--7.86 (m, 1H), 8.18 (s, 1H), 8.32 (dd, *J* = 7.9, 0.9 Hz, 1H), 8.47 (d, *J* = 8.1 Hz, 1H), 11.59 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 20.7, 116.0, 117.2, 122.3, 123.1, 125.5, 127.3, 127.7, 130.1, 130.9, 132.5, 134.3, 134.4, 160.7.

### 4-Methylphenanthridin-6(5*H*)-one (**2r**)^[@cit18m]^ {#sec4.2.19}

*R*~f~ = 0.53. White solid (52 mg, 83%). mp 237--240 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.51 (s, 3H), 7.20 (t, *J* = 7.7 Hz, 1H), 7.38--7.40 (m, 1H), 7.62--7.65 (m, 1H), 7.86--7.89 (m, 1H), 8.27--8.29 (m, 1H), 8.35 (d, *J* = 8.1 Hz, 1H), 8.52--8.54 (m, 1H), 10.76 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 17.3, 117.7, 121.3, 122.4, 122.9, 124.5, 125.3, 127.5, 128.0, 131.1, 133.1, 134.6, 135.0, 161.2.

### 8,9-Dimethoxyphenanthridin-6(5*H*)-one (**2t**)^[@ref15]^ {#sec4.2.20}

*R*~f~ = 0.52. White solid (60 mg, 78%). mp 292--294 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.91 (s, 3H), 4.03 (s, 3H), 7.24 (d, *J* = 7.5 Hz, 1H), 7.33--7.36 (m, 1H), 7.42--7.45 (m, 1H), 7.73 (s, 1H), 7.89 (s, 1H), 8.38 (d, *J* = 7.7 Hz, 1H), 11.58 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 56.0, 56.6, 104.7, 108.4, 116.4, 118.0, 119.8, 122.5, 123.5, 129.1, 129.8, 136.6, 149.8, 153.7, 160.9.

### 9-Methylphenanthridin-6(5*H*)-one (**2u**)^[@cit18a]^ {#sec4.2.21}

*R*~f~ = 0.56. White solid (42 mg, 67%). mp 249--251 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.53 (s, 3H), 7.24--7.27 (m, 1H), 7.33--7.37 (m, 1H), 7.45--7.50 (m, 2H), 8.21 (d, *J* = 8.1 Hz, 1H), 8.31 (s, 1H), 8.36 (dd, *J* = 8.0, 1.0 Hz, 1H), 11.57 (s, 1H); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.6, 116.1, 117.6, 122.0, 122.5, 123.2, 123.4, 127.5, 129.1, 129.5, 134.3, 136.7, 143.0, 160.9.

Experimental Procedure for the Mechanism Study {#sec4.3}
----------------------------------------------

To a 5 mL microwave reaction tube was added **1a** or **1v** (0.3 mmol), **4** (0.122 g, 0.6 mmol), K~2~CO~3~ (0.208 g, 1.5 mmol), and DMF (3 mL). After stirring at room temperature for 5 min followed by flushing with N~2~ and sealing the tube, the reaction mixture was stirred at 150 °C for 2 h by microwave irradiation at 100 W initial power. The mixture was cooled to room temperature and filtered through a short silica gel column (ethyl acetate) to eliminate inorganic salts. Evaporation of the solvent under reduced pressure gave a crude mixture, which was separated by TLC (hexane/ethyl acetate = 2:1) to afford **5**.

### *N*-Phenyl-3,4,5,6-tetrahydro-\[1,1′-biphenyl\]-2-carboxamide (**5a**) {#sec4.3.1}

*R*~f~ = 0.63. Pale yellow solid (12 mg, 14%). mp 97--99 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.68--1.73 (m, 2H), 1.76--1.80 (m, 2H), 2.44--2.47 (m, 2H), 2.80--2.82 (m, 2H), 6.66 (s, 1H), 6.98--7.00 (m, 2H), 7.02--7.05 (m, 1H), 7.16--7.20 (m, 2H), 7.29--7.36 (m, 3H), 7.46--7.48 (m, 2H); ^13^C NMR (125 MHz, CDCl~3~): δ 22.1, 23.7, 28.6, 35.4, 120.0, 124.8, 127.9, 128.5, 128.8, 128.9, 129.5, 136.2, 136.9, 139.5, 165.9. HRMS (EI): Anal. Calcd for C~19~H~19~NO (M^+^), 277.1467; found, 277.1469.

### *N*-(2,6-Dimethylphenyl)-3,4,5,6-tetrahydro-\[1,1′-biphenyl\]-2-carboxamide (**5b**) {#sec4.3.2}

*R*~f~ = 0.57. Pale yellow solid (56 mg, 61%). mp 115--117 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.69--1.73 (m, 2H), 1.76--1.81 (m, 2H), 2.30 (s, 6H), 2.46--2.49 (m, 2H), 2.80--2.82 (m, 2H), 6.80 (s, 1H), 7.08--7.10 (m, 2H), 7.11--7.17 (m, 3H), 7.50--7.53 (m, 2H), 7.56--7.59 (m, 1H); ^13^C NMR (125 MHz, CDCl~3~): δ 18.8, 21.5, 24.2, 29.8, 36.4, 118.8, 120.7, 127.4, 127.5, 128.27, 128.31, 130.1, 134.5, 135.6, 135.7, 167.4. HRMS (EI): Anal. Calcd for C~21~H~23~NO (M^+^), 305.1780; found, 305.1781.
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